Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

PURPOSE: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” EXPERIMENTAL DESIGN: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7985967/
https://ncbi.nlm.nih.gov/pubmed/29298798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2653
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items